Company Overview and News

0
Currency Exchange International Announces Financial Results for the Three and Six Month Periods Ended April 30, 2018

2018-05-31 globenewswire
TORONTO, May 31, 2018 (GLOBE NEWSWIRE) -- Currency Exchange International, Corp. (the “Company”) (TSX:CXI) (OTCBB:CURN), is pleased to announce its financial results and present management's discussion and analysis ("MD&A") for the three and six month period ended April 30, 2018 (all figures are in U.S. dollars except where otherwise indicated). The complete financial statements and MD&A can be found on the Company's SEDAR profile at www.
CXI EXSR CURN

0
Currency Exchange International Announces Voting Results from Annual General Meeting March 15, 2018

2018-03-16 globenewswire
TORONTO, March 16, 2018 (GLOBE NEWSWIRE) -- Currency Exchange International, Corp. (TSX:CXI) (OTC Pink:CURN) (the "Company") is pleased to announce the detailed voting results for the election of its Board of Directors, which took place at the Company's Annual General Meeting held on March 15, 2018 (the "Meeting"). The nominees listed in the management information circular dated January 24, 2018 were elected as directors of the Company at the Meeting.
CXI CURN

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to TSX:CXI / Currency Exchange Intern on message board site Silicon Investor.

Acxiom (ACXM) CXII - Commodore Applied Technologies, Inc.
CXI-Commodore Environmental Coflexip ADR CXIPY Flexible Drilling Pipe
CXIL - CHEM INTL INC DCX INC. DCXI
Corsair Exploration CXI A DCXI INC.- MAY QTR. REVENUES UP 249%